Overview

• European regulators cleared new anti-amyloid therapies that slow decline by about 30%, but Spain has not yet approved or funded their use.
• Asturias has formed a working group and is designing protocols for intravenous hospital dispensing and radiological monitoring required for the new treatments.
• Catalonia’s Bellvitge–ADmit Therapeutics blood biomarker obtained the EU IVDF seal for clinical use, while HUCA is validating blood markers with patient samples.
• Clinicians report more early and younger-onset detections alongside frequent diagnostic delays, with families citing out-of-pocket costs averaging €35,000 a year.
• Non-pharmacological supports expand, including Madrid’s early-onset day centre, prevention programs focused on exercise and cognitive stimulation, and an adapted museum visit in Durango scheduled for October.